Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer

Figure 1 EGF-induced EGFR- and ERK1/2-activation in HCC cells.

Figure 2 Erlotinib inhibited EGFR (A) and ERK1/2 (B) activation in HCC cells.

Figure 3 STAT-expression and EGF-induced activation in HCC cells. EGF induced STAT activation could be shown for STATs 1 and 3 (A and B) but not in the case of STAT5 (C).

Figure 4 Erlotinib inhibited STAT-activation in HCC cells.

Figure 5 Erlotinib modulated the expression of cell cycle regulators (A) and antiapoptotic members of the Bcl-2 family (B and C).

Figure 6 IGF-1-induced activation of ERK1/2 and transactivation of the EGFR.

Figure 7 Erlotinib inhibited EGF and/or IGF-1-induced ERK1/2-activation and EGFR/IGF-1R cross talk.

Figure 8 Erlotinib did not influence IGF-1R expression or activation.

Figure 9 Antiproliferative effects of erlotinib plus AG1024. A: HepG2; B: Huh-7.